<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1405-9940</journal-id>
<journal-title><![CDATA[Archivos de cardiología de México]]></journal-title>
<abbrev-journal-title><![CDATA[Arch. Cardiol. Méx.]]></abbrev-journal-title>
<issn>1405-9940</issn>
<publisher>
<publisher-name><![CDATA[Instituto Nacional de Cardiología Ignacio Chávez]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1405-99402018000400287</article-id>
<article-id pub-id-type="doi">10.1016/j.acmx.2018.01.003</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Un novedoso agente en el tratamiento de la insuficiencia cardiaca con función sistólica deprimida]]></article-title>
<article-title xml:lang="en"><![CDATA[A novel agent in the treatment of heart failure with depressed systolic function]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Duarte-Vera]]></surname>
<given-names><![CDATA[Yan C.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
<xref ref-type="aff" rid="A a"/>
<xref ref-type="aff" rid="A4"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Cáceres-Vinueza]]></surname>
<given-names><![CDATA[Silvia V.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Daher-Nader]]></surname>
<given-names><![CDATA[Jorge E.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Lara-Terán]]></surname>
<given-names><![CDATA[Joffre F.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Facultad de Ciencia Medicas de la Universidad de Guayaquil  ]]></institution>
<addr-line><![CDATA[ Guayaquil]]></addr-line>
<country>Ecuador</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Hospital General Luis Vernaza Servicio de Cardiología ]]></institution>
<addr-line><![CDATA[ Guayaquil]]></addr-line>
<country>Ecuador</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Sociedad de Lucha contra el Cáncer  ]]></institution>
<addr-line><![CDATA[ Guayaquil]]></addr-line>
<country>Ecuador</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,Sociedad Ecuatoriana de Cardiología  ]]></institution>
<addr-line><![CDATA[ Guayaquil]]></addr-line>
<country>Ecuador</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2018</year>
</pub-date>
<volume>88</volume>
<numero>4</numero>
<fpage>287</fpage>
<lpage>297</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S1405-99402018000400287&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S1405-99402018000400287&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S1405-99402018000400287&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Introducción:  Se revisará la evolución del tratamiento farmacológico de la insuficiencia cardiaca (IC) en los últimos 25 an&#732;os, desde el concepto de tratamiento con vasodilatadores, pasando por el bloqueo o inhibición del sistema renina-angiotensina-aldosterona y la inhibición betaadrenérgica y su importante contribución en la disminución de la morbimortalidad por IC, el papel de los péptidos natriuréticos y, finalmente, se conocerá uno de los estudios más importantes en el área cardiológica y específicamente en el manejo de la IC, en el cual se demuestra un enfoque modulador de los sistemas neuro humorales que se activan en estos pacientes.  Objetivos:  La IC constituye la etapa final de la mayoría de las enfermedades cardiovasculares, con una alta tasa de hospitalización y de morbimortalidad cardiovascular, siendo, por lo tanto, de interés constante la necesidad de encontrar un agente terapéutico innovador que disminuya significativamente estas complicaciones y también que mejore la calidad de vida de los que la presentan.  Metodología:  Se realizará una descripción del PARADIGM-HF Clinical Trial, que utilizó un compuesto sacubitrilo/valsartán para el manejo de la IC con un mecanismo modulador diferente del concepto de bloqueador de sistemas deletéreos que se activan cuando un paciente presenta síntomas y signos de IC.  Conclusiones:  La muerte por causas cardiovasculares u hospitalización por IC (el punto final primario) se produjo en 914 pacientes (21.8%) en el grupo sacubitrilo/valsartán y 1,117 pacientes (26.5%) en el grupo de enalapril (razón de riesgo en el grupo sacubitrilo/valsartán, 0.80; intervalo de confianza (IC) del 95%: 0.73 a 0.87; p &lt; 0.001 (exacta p = 4.0 × 10 - 7)). De los pacientes que recibieron sacubitrilo/valsartán, 537 (12.8%) fueron hospitalizados por IC, en comparación con los 658 pacientes (15.6%) que recibieron enalapril (razón de riesgo, 0.79; IC del 95%, 0.71 a 0.89; p &lt; 0.001). Un total de 711 pacientes (17.0%) en el grupo sacubitrilo/valsartán y 835 pacientes (19.8%) en el grupo de enalapril murió (razón de riesgo de muerte por cualquier causa, 0.84; IC del 95%, 0.76 a la 0.93; p &lt; 0.001).]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Introduction:  A review is presented on the evolution of the pharmacological treatment of heart failure (HF) in the last 25 years, from the concept of treatment with vasodilators to the blocking or inhibition of the renin angiotensin aldosterone system. Beta-adrenergic inhibition and its important contribution in the reduction of morbidity and mortality due to HF will be discussed along with the role of the natriuretic peptides. One of the most important studies in the cardiology area, and specifically in the management of HF, is presented, in which an approach is demonstrated of the modulator of the neurohumoral systems that are activated in these patients.  Objectives:  HF is the final stage of most cardiovascular diseases, and has a high rate of hospital admission, as well as cardiovascular morbidity and mortality. Therefore, there is constant interest in the need to find an innovative therapeutic agent that significantly reduces these complications and that improves the quality of life of those who suffer from it.  Methods:  A description will be presented of the PARADIGM-HF Clinical Trial using a sacubitril/valsartán compound for the management of HF with a modulating mechanism different from the concept of a deleterious system blocker that is activated when a patient has symptoms and signs of heart failure.  Conclusions:  Death due to cardiovascular causes, or hospital admission due to heart failure (the primary endpoint) occurred in 914 patients (21.8%) in the Sacubitril / valsartán group, and 1117 patients (26.5%) in the enalapril group (risk ratio in the sacubitril / valsartán group, 0.80, with a 95% confidence interval [CI]: 0.73 to 0.87, P&lt;0.001 ;exact P= 4.0 × 10 --7;). Of the patients receiving sacubitril / valsartán, 537 (12.8%) were hospitalised due to heart failure, compared with 658 patients (15.6%) receiving enalapril (hazard ratio 0.79, 95% CI: 0.71 to 0.89, P&lt;.001). A total of 711 patients (17.0%) in the sacubitril / valsartán group, and 835 patients (19.8%) in the enalapril group, died (all-cause death rate, 0.84, 95% CI: 0.76 to 0.93, P&lt;.001)]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Nesiritida]]></kwd>
<kwd lng="es"><![CDATA[Insuficiencia cardiaca]]></kwd>
<kwd lng="es"><![CDATA[Péptido natriurético tipo B]]></kwd>
<kwd lng="es"><![CDATA[Fracción eyección reducida]]></kwd>
<kwd lng="es"><![CDATA[Ecuador]]></kwd>
<kwd lng="en"><![CDATA[Nesiritide]]></kwd>
<kwd lng="en"><![CDATA[Heart failure]]></kwd>
<kwd lng="en"><![CDATA[Type B-natriuretic peptide]]></kwd>
<kwd lng="en"><![CDATA[Reduced ejection fraction]]></kwd>
<kwd lng="en"><![CDATA[Ecuador]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ponikowski]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Voors]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Anker]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Guía ESC 2016 Sobre el diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica]]></article-title>
<source><![CDATA[Rev Esp Cardiol.]]></source>
<year>2016</year>
<volume>69</volume>
<page-range>e1-85</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yancy]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Jessup]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Bozkurt]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[2013 ACCF/AHA Guideline for the management of heart failure]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2013</year>
<volume>62</volume>
<page-range>e147-239</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kenchaiah]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Evans]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Levy]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[al]]></surname>
<given-names><![CDATA[et]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Obesity and the risk of heart failure]]></article-title>
<source><![CDATA[N Engl J Med.]]></source>
<year>2002</year>
<volume>347</volume>
<page-range>305-13</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[McMurray]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Systolic heart failure]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2010</year>
<volume>362</volume>
<page-range>228-38</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cohn]]></surname>
<given-names><![CDATA[JN]]></given-names>
</name>
<name>
<surname><![CDATA[Archibld]]></surname>
<given-names><![CDATA[DG]]></given-names>
</name>
<name>
<surname><![CDATA[Ziesche]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study]]></article-title>
<source><![CDATA[N Engl J Med.]]></source>
<year>1986</year>
<volume>314</volume>
<page-range>1547-52</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cohn]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of vasodilator therapy on mortality in chronic congestive heart failure.]]></article-title>
<source><![CDATA[Eur Heart J]]></source>
<year>1988</year>
<volume>9</volume>
<page-range>171-3</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cohn]]></surname>
<given-names><![CDATA[JN]]></given-names>
</name>
<name>
<surname><![CDATA[Johnson]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Ziesche]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure]]></article-title>
<source><![CDATA[N Engl J Med.]]></source>
<year>1991</year>
<volume>325</volume>
<page-range>303-10</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8.</label><nlm-citation citation-type="journal">
<collab>CONSENSUS</collab>
<article-title xml:lang=""><![CDATA[Effects of enalapril on mortality in severe congestive heart failure. Results of the CooperativeNorth Scandinavian Enalapril Survival Study (CONSENSUS)]]></article-title>
<source><![CDATA[N Engl J Med.]]></source>
<year>1987</year>
<volume>316</volume>
<page-range>1429-35</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9.</label><nlm-citation citation-type="journal">
<collab>Investigators The SOLVD</collab>
<article-title xml:lang=""><![CDATA[Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>1991</year>
<volume>325</volume>
<page-range>293-302</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sacks]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Jarcho]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Curfman]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Paradigm shifts in heart- failure therapy ---A timeline.]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2014</year>
<volume>371</volume>
<page-range>989-91</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cohn]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Tognoni]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A randomized trial of the angiotensinreceptor blocker valsartan in chronic heart failure]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2001</year>
<volume>345</volume>
<page-range>1667-75</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12.</label><nlm-citation citation-type="journal">
<collab>CIBIS Investigators</collab>
<article-title xml:lang=""><![CDATA[A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). CIBIS Investigators and Committees]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>1990</year>
<volume>90</volume>
<page-range>1765-73</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13.</label><nlm-citation citation-type="journal">
<collab>CIBIS-II Investigators Committees</collab>
<article-title xml:lang=""><![CDATA[The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>1999</year>
<volume>353</volume>
<page-range>9-13</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Willenheimer]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[van Veldhuisen]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
<name>
<surname><![CDATA[Silke]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence: Results of the Randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2005</year>
<volume>112</volume>
<page-range>2426-35</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Packer]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of carvedilol on the morbidity of patients with severe chronic heart failure: Results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2002</year>
<volume>106</volume>
<page-range>2194-9</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hjalmarson]]></surname>
<given-names><![CDATA[Å]]></given-names>
</name>
<name>
<surname><![CDATA[Goldstein]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Fagerberg]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>2000</year>
<volume>283</volume>
<page-range>1295</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pitt]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Zannad]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Remme]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>1999</year>
<volume>341</volume>
<page-range>709-17</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dhillon]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Eplerenone: A review of its use in patients with chronic systolic heart failure and mild symptoms]]></article-title>
<source><![CDATA[Drugs]]></source>
<year>2013</year>
<volume>73</volume>
<page-range>1451-62</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kelly]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Smith]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Digoxin in heart failure: Implications of recent trials]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>1993</year>
<volume>22</volume>
<page-range>A107</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yusuf]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Wittes]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Bailey]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Digitalis a new controversy regarding an old drug. The pitfalls of inappropriate methods]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>1986</year>
<volume>73</volume>
<page-range>14-8</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jaeschke]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Guyatt]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Oxman]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[To what extent do congestive heart failure patients in sinus rhythm benefit from digoxin therapy? A systematic overview and metaanalysis]]></article-title>
<source><![CDATA[Am J Med]]></source>
<year>1990</year>
<volume>88</volume>
<page-range>279-86</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Perry]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Brown]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The effect of digoxin on mortality and morbidity in patients with heart failure]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>1997</year>
<volume>336</volume>
<page-range>525-33</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Faris]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Flather]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Purcell]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Current evidence supporting the role of diuretics in heart failure: A meta-analysis of randomized controlled trials]]></article-title>
<source><![CDATA[Int J Cardiol]]></source>
<year>2002</year>
<volume>82</volume>
<page-range>149-58</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[De Teresa]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tratamiento diurético de la insuficiencia cardiaca]]></article-title>
<source><![CDATA[Rev Esp Cardiol Supl.]]></source>
<year>2007</year>
<volume>7</volume>
<page-range>34F-44F</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Martinez-Rumayor]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Richards]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Burnett]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Biology of the natriuretic peptides]]></article-title>
<source><![CDATA[Am J Cardiol.]]></source>
<year>2008</year>
<volume>101</volume>
<page-range>S3-8</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pandey]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Biology of natriuretic peptides and their receptors]]></article-title>
<source><![CDATA[Peptides]]></source>
<year>2005</year>
<volume>26</volume>
<page-range>901-32</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Collinson]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Natriuretic peptides----A review]]></article-title>
<source><![CDATA[Eur Cardiol]]></source>
<year>2005</year>
<volume>1</volume>
<page-range>66-9</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Epstein]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Levin]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Gardner]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Natriuretic peptides.]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>1998</year>
<volume>339</volume>
<page-range>321-8</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mangiafico S]]></surname>
<given-names><![CDATA[Costello-Boerrigter L]]></given-names>
</name>
<name>
<surname><![CDATA[Andersen]]></surname>
<given-names><![CDATA[etal.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics.]]></article-title>
<source><![CDATA[Eur Heart J]]></source>
<year>2012</year>
<volume>34</volume>
<page-range>886-93</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30.</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Potter]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Yoder]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Flora]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Natriuretic peptides: Their structures, receptors, physiologic functions and therapeutic applications]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Schmidt]]></surname>
<given-names><![CDATA[HHHW]]></given-names>
</name>
<name>
<surname><![CDATA[Hofmann]]></surname>
<given-names><![CDATA[FB]]></given-names>
</name>
<name>
<surname><![CDATA[Stasch]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
</name>
</person-group>
<source><![CDATA[cGMP:Generators Effectors and Therapeutic Implications]]></source>
<year>2009</year>
<page-range>341-66</page-range><publisher-loc><![CDATA[Berlin,Heidelberg ]]></publisher-loc>
<publisher-name><![CDATA[Springer Verlag]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B31">
<label>31.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Larson]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Levy]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[al.]]></surname>
<given-names><![CDATA[et]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Plasma natriuretic peptide levels and the risk of cardiovascular events and death]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2004</year>
<volume>350</volume>
<page-range>655-63</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>32.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kragelund]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Grønning]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Køber]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[N-terminal pro---B- type natriuretic peptide and long-term mortality in stable coronary heart disease.]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2005</year>
<volume>352</volume>
<page-range>666-75</page-range></nlm-citation>
</ref>
<ref id="B33">
<label>33.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ceyhan]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Unal]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Yenisey]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The role of the N-terminal pro-brain natriuretic peptide in the evaluation of left ventricular diastolic dysfunction: correlation with echocardiographic indexes in hypertensive patients]]></article-title>
<source><![CDATA[Int J Cardiovasc Imaging.]]></source>
<year>2007</year>
<volume>24</volume>
<page-range>253-9</page-range></nlm-citation>
</ref>
<ref id="B34">
<label>34.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Latini]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT]]></article-title>
<source><![CDATA[Eur Heart J.]]></source>
<year>2004</year>
<volume>25</volume>
<page-range>292-9</page-range></nlm-citation>
</ref>
<ref id="B35">
<label>35.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zanchi]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Maillard]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Burnier]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Recent clinical trials with omapatrilat: New developments]]></article-title>
<source><![CDATA[Curr Hypertens Rep.]]></source>
<year>2003</year>
<volume>5</volume>
<page-range>346-52</page-range></nlm-citation>
</ref>
<ref id="B36">
<label>36.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kostis]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Omapatrilat and enalapril in patients with hypertension: The Omapatrilat Cardiovascular Treatment vs Enalapril (OCTAVE) trial.]]></article-title>
<source><![CDATA[Am J Hypertens]]></source>
<year>2004</year>
<volume>17</volume>
<page-range>103-11</page-range></nlm-citation>
</ref>
<ref id="B37">
<label>37.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Manzur]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Villarreal]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Moneriz]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Inhibición dual de la neprilisina y el receptor de angiotensina ii: nueva estrategia prometedora en el tratamiento de la enfermedad cardiovascular]]></article-title>
<source><![CDATA[Rev Colomb Cardiol]]></source>
<year>2013</year>
<volume>20</volume>
<page-range>386-93</page-range></nlm-citation>
</ref>
<ref id="B38">
<label>38.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[McMurray]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Packer]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Desai]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Angiotensinneprilysin Inhibition versus enalapril in heart failure]]></article-title>
<source><![CDATA[N Engl J Med.]]></source>
<year>2014</year>
<volume>371</volume>
<page-range>993-1004</page-range></nlm-citation>
</ref>
<ref id="B39">
<label>39.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Seferovic]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Claggett]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Seidelmann]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial.]]></article-title>
<source><![CDATA[Lancet Diabetes Endocrinol]]></source>
<year>2017</year>
<volume>5</volume>
<page-range>333-40</page-range></nlm-citation>
</ref>
<ref id="B40">
<label>40.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jing]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Mogi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Horiuchi]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Role of reninangiotensin-aldosterone system in adipose tissue dysfunction]]></article-title>
<source><![CDATA[Mol Cell Endocrinol.]]></source>
<year>2013</year>
<volume>378 (1-2)</volume>
<page-range>23-8</page-range></nlm-citation>
</ref>
<ref id="B41">
<label>41.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Willard]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Barrow]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Zraika]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Improved glycaemia in high-fat-fed neprilysin-deficient mice is associated withreduced DPP-4 activity and increased active GLP-1 levels.]]></article-title>
<source><![CDATA[Diabetologia]]></source>
<year>2016</year>
<volume>60</volume>
<page-range>701---8</page-range></nlm-citation>
</ref>
<ref id="B42">
<label>42.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lazo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Young]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Brancati]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[NH2-terminal probrain natriuretic peptide and risk of diabetes]]></article-title>
<source><![CDATA[Diabetes]]></source>
<year>2013</year>
<volume>62</volume>
<page-range>3189-93</page-range></nlm-citation>
</ref>
<ref id="B43">
<label>43.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mori]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Sales]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Motta]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Kinin B1 receptor in adipocytes regulates glucose tolerance and predisposition to obesity.]]></article-title>
<source><![CDATA[Plos ONE]]></source>
<year>2012</year>
<volume>7</volume>
</nlm-citation>
</ref>
<ref id="B44">
<label>44.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Plamboeck]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Holst]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Carr]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Neutral endopeptidase 24.11 and dipeptidyl peptidase iv are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig.]]></article-title>
<source><![CDATA[Diabetologia]]></source>
<year>2005</year>
<volume>48</volume>
<page-range>1882-90</page-range></nlm-citation>
</ref>
<ref id="B45">
<label>45.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Messerli]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Angiotensin ii receptor inhibition]]></article-title>
<source><![CDATA[Arch Intern Med]]></source>
<year>1996</year>
<volume>156</volume>
<page-range>1957</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
